MAPK9 and acute myeloid leukemia: In human AML cells, the combination of PTL and pan-histone deacetylase inhibitors (HDACIs) potentiates HDACI lethality by blocking NF-κB and subsequent MKK7-dependent activation of the SAPK/JNK pathway [67].